Fig. 6From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case seriesChanges in circulating T cells. (a) Percentages of circulating CD4 and CD8 T cells in complete and partial responders responders before and after T-VEC plus pembrolizumab (b) CD4:CD8 ratios complete and partial responders responders before and after T-VEC plus pembrolizumab. (c) Percentages of PD1+ CD4 and CD8 T cells in complete and partial responders responders before and after T-VEC plus pembrolizumabBack to article page